BeiGene (BGNE) Stock Price, News & Analysis

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BeiGene in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" BGNE shares.
View BGNE analyst ratings or view top-rated stocks.

10 Wall Street analysts have issued twelve-month target prices for BeiGene's shares. Their BGNE share price targets range from $161.00 to $345.00. On average, they anticipate the company's share price to reach $250.13 in the next twelve months. This suggests a possible upside of 52.1% from the stock's current price.
View analysts price targets for BGNE or view top-rated stocks among Wall Street analysts.

BeiGene's stock was trading at $180.36 at the beginning of the year. Since then, BGNE stock has decreased by 8.8% and is now trading at $164.44.
View the best growth stocks for 2024 here.

BeiGene saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,840,000 shares, an increase of 6.4% from the March 31st total of 1,730,000 shares. Based on an average daily volume of 246,200 shares, the short-interest ratio is presently 7.5 days.
View BeiGene's Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our BGNE earnings forecast.

BeiGene, Ltd. (NASDAQ:BGNE) posted its earnings results on Monday, February, 26th. The company reported ($3.53) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.61) by $0.08. The business earned $634.40 million during the quarter, compared to analysts' expectations of $632.52 million. BeiGene had a negative trailing twelve-month return on equity of 23.12% and a negative net margin of 35.86%. The business's revenue for the quarter was up 66.9% on a year-over-year basis. During the same period last year, the company posted ($4.29) earnings per share.

ETFs with the largest weight of BeiGene (NASDAQ:BGNE) stock in their portfolio include Morningstar US Small Growth (MSGR), First Trust NYSE Arca Biotechnology Index Fund (FBT), VanEck Biotech ETF (BBH), Tema Oncology ETF (CANC), Virtus LifeSci Biotech Products ETF (BBP), Global X Aging Population ETF (AGNG), iShares Biotechnology ETF (IBB) and Invesco Nasdaq Biotechnology ETF (IBBQ).

58 employees have rated BeiGene Chief Executive Officer John V. Oyler on Glassdoor.com. John V. Oyler has an approval rating of 69% among the company's employees. 42.0% of employees surveyed would recommend working at BeiGene to a friend.

Based on aggregate information from My MarketBeat watchlists, some companies that other BeiGene investors own include NVIDIA (NVDA), Alibaba Group (BABA), CRISPR Therapeutics (CRSP), Block (SQ), Intuitive Surgical (ISRG), JD.com (JD), Intel (INTC), Baidu (BIDU), Marvell Technology (MRVL) and Cisco Systems (CSCO).

BeiGene (BGNE) raised $126 million in an initial public offering (IPO) on Wednesday, February 3rd 2016. The company issued 5,500,000 shares at a price of $22.00-$24.00 per share. Goldman Sachs, Morgan Stanley and Cowen and Company acted as the underwriters for the IPO and Baird was co-manager.

BeiGene's stock is owned by many different retail and institutional investors. Top institutional shareholders include Baillie Gifford & Co. (3.90%), BNP PARIBAS ASSET MANAGEMENT Holding S.A. (0.10%), Edmond DE Rothschild Holding S.A. (0.10%), Van ECK Associates Corp (0.09%), Barings LLC (0.03%) and XY Capital Ltd (0.03%). Insiders that own company stock include Advisors Ltd Hhlr, Amgen Inc, Chan Henry Lee, Corazon (Corsee) D Sanders, Howard Liang, Jane Huang, John Oyler, Julia Aijun Wang, Lai Wang, Ltd Beigene, Timothy Yung-Cheng Chen, Xiaobin Wu and Xiaodong Wang.
View institutional ownership trends.

Shares of BGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.